Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD

Introduction: Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXIRx is a novel strategy that may safely reduce the risk of thrombotic events. Methods: This multicenter...

Full description

Bibliographic Details
Main Authors: Michael Walsh, Claudette Bethune, Andrew Smyth, Jessica Tyrwhitt, Shiangtung W. Jung, Rosie Z. Yu, Yanfeng Wang, Richard S. Geary, Jeffrey Weitz, Sanjay Bhanot
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Kidney International Reports
Subjects:
anticoagulation
antisense oligonucleotide
FXI
hemodialysis
pharmacokinetics
randomized controlled trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024921015175

Internet

http://www.sciencedirect.com/science/article/pii/S2468024921015175

Similar Items